BMY News and Press, Bristol-Myers Squibb Company From 06/11/24

2024-06-11 01:15:00 ET Summary The Morningstar Wide Moat Focus Index faced challenges in May due to its equal-weighting, value stock bias and lack of mega-cap tech exposure. History may provide context for what comes next. US equities re-initiated their upward trend in May, with m...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

2024-06-09 05:15:00 ET Summary Structure Therapeutics raises $476 million through an offering of its ADSs after announcing positive clinical results for its obesity drug. Suzhou Alphamab Oncology partners with ArriVent BioPharma to develop antibody drug conjugates, potentially rec...

2024-06-09 03:34:01 ET Summary Bristol Myers Squibb has solid fundamentals that have been clouded by the rise of interest rates. The company's revenue is at risk due to higher debt burdens and future patent expiry concerns, but recent acquisitions and cost-saving measures provide ...

2024-06-08 10:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-08 10:19:47 ET More on Bristol Myers Squibb Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Gener...

2024-06-08 10:19:36 ET More on AstraZeneca, Bristol-Myers, etc. Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript) Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly ...

2024-06-08 09:30:00 ET Summary This article is for income investors who prioritize income over growth. We will discuss two alternatives; the first one is for folks who want to keep things simple and diversified. This makes investments in just eight funds and could potentially gene...

2024-06-08 08:00:00 ET Summary The FDA approved Geron's Rytelo for specific low-risk MDS patients, a significant milestone for the company. Rytelo faces stiff competition in the MDS market, particularly from drugs like Reblozyl, which limits its market share. Geron's financial...

2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...